GLP-1s are a breakthrough, but they are not the end of the story. To ensure lasting success, we must pair pharmacological interventions with behavioral support, personalized data, and continuous guidance. The post Beyond the Prescription: Supporting Long-Term Metabolic Health After GLP-1s appeared first on MedCity News.
[Sponsored] At a time when AI is reshaping pharma, Reverba Global CEO Cheryl Lubbert explained in an interview why empathy, context, and ethics still require a human touch. The post The Human Algorithm: What AI Can’t Replace in Pharma Engagement appeared first on MedCity News.
Samsung announced plans to acquire Xealth, a startup that helps hospitals integrate digital tools into clinical workflows, as part of its broader push into U.S. healthcare. The deal reflects growing provider demand for tech solutions and comes amid newfound optimism in the digital health exit market. The post Samsung Deepens Healthcare Bet With Xealth Acquisition…
Novartis malaria drug Coartem has expanded its approval to include babies. The combination drug, originally formulated as a tablet, has a new dose strength and formulation designed for treating newborns and young infants who develop malarial infections. The post Novartis Drug Becomes First Malaria Therapy for Newborns and Infants appeared first on MedCity News.
[Sponsored] Neurologists and health care practitioners must evolve with the world. Telemedicine carts assist in this evolution by serving as an intermediary between patients and doctors. The post The 3 Best Options to Buy Telemedicine Carts for Neurology Care appeared first on MedCity News.
The industry needs smart conversations that challenge assumptions and invite the full spectrum of voices to the table to ensure technology evolves in a way that’s not only clinically sound, but ethically aligned with what patients and providers need most. The post The Future of Surgery: Bridging Innovation and Collaboration appeared first on MedCity News.
Every day, patients are making agonizing choices to skip medications due to cost, and the fallout is evident in worsening health and avoidable hospitalizations. Health systems are in a prime position to break this cycle by acting as advocates for their patients’ financial as well as physical well-being. The post When Cost Blocks Care: Why Medication…
Demonstrating the clinical utility and cost-effectiveness of innovative blood-based biomarker tests can help pave the way for making timely AD diagnosis and proactive care the norm. The post Broadening Biomarker Validation for Alzheimer’s Disease Diagnosis Globally appeared first on MedCity News.
Digital health funding held steady in the first half of 2025, with AI-focused startups capturing the majority of capital and driving rapid adoption among providers. The digital health space also saw two long-awaited IPOs as well as rising M&A activity, which are two signals of market maturity — but looming policy shifts may challenge long-term…
KalVista Pharmaceuticals’ Ekterly is now FDA approved for treating acute swelling attacks from hereditary angioedema. The KalVista tablet provides an alternative to injectable or infused HAE medications from companies such as Takeda Pharmaceutical and CSL Behring. The post KalVista Drug Gets FDA Approval for Treating Acute Swelling Attacks From Rare Disease appeared first on MedCity…